TrialNeuro-oncology2012

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.

Bret B Friday et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.